The Medicines Company (NASDAQ:MDCO) Given Average Rating of “Hold” by Analysts

Shares of The Medicines Company (NASDAQ:MDCO) have received an average recommendation of “Hold” from the eighteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $71.62.

MDCO has been the topic of a number of recent research reports. Piper Jaffray Companies reaffirmed a “positive” rating and set a $145.00 price objective (up from $142.00) on shares of The Medicines in a report on Monday, September 2nd. Citigroup reaffirmed a “hold” rating and set a $59.00 price objective on shares of The Medicines in a research report on Wednesday, November 20th. Bank of America reiterated a “buy” rating and set a $51.00 price objective on shares of The Medicines in a report on Monday, August 26th. Jefferies Financial Group lowered The Medicines from a “buy” rating to a “hold” rating and lifted their target price for the company from $44.00 to $50.00 in a research report on Thursday, October 10th. Finally, Cowen restated a “buy” rating and issued a $60.00 target price on shares of The Medicines in a research note on Monday, November 25th.

Shares of NASDAQ:MDCO traded up $0.10 during midday trading on Tuesday, reaching $84.01. 329,545 shares of the company’s stock were exchanged, compared to its average volume of 6,420,317. The company’s 50 day simple moving average is $61.06 and its two-hundred day simple moving average is $44.70. The firm has a market capitalization of $6.71 billion, a PE ratio of -28.87 and a beta of 1.09. The Medicines has a 12 month low of $16.69 and a 12 month high of $84.30. The company has a debt-to-equity ratio of 21.45, a quick ratio of 0.77 and a current ratio of 0.77.

The Medicines (NASDAQ:MDCO) last issued its earnings results on Wednesday, October 30th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.12). During the same quarter last year, the business posted ($0.70) EPS. On average, research analysts anticipate that The Medicines will post -3.42 earnings per share for the current year.

Large investors have recently bought and sold shares of the business. Advisory Services Network LLC acquired a new stake in shares of The Medicines in the 2nd quarter valued at approximately $35,000. Meeder Asset Management Inc. bought a new position in shares of The Medicines in the second quarter valued at $44,000. Tower Research Capital LLC TRC increased its holdings in The Medicines by 1,156.3% during the third quarter. Tower Research Capital LLC TRC now owns 2,186 shares of the company’s stock worth $109,000 after buying an additional 2,012 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its holdings in The Medicines by 17.8% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,526 shares of the company’s stock worth $92,000 after buying an additional 381 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in The Medicines by 705.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock worth $145,000 after acquiring an additional 2,540 shares in the last quarter.

About The Medicines

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.

See Also: Conference Calls and Individual Investors

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.